Investment analysts and portfolio managers look into their crystal balls to predict the best-performing stocks for the year ahead.
Medical cannabis company wants to raise $4.1m to take it from startup to revenue-generating business.
The NZX-listed trust lifted its underlying profit by 18%.
New chair acknowledges investors ‘confused’ by lack of dividend.
Headwinds are priced in already – but will company forecasts provide a glimmer of hope to shareholders?
The cannabis company is confident revenue isn't far off, but material uncertainty exists.
Negative quarter as funds hit by Covid-19 and Ukraine market jitters.
Sellers of Avgas and Jet A1 cut prices to general aviation market.
But uncertainty clouds the horizon at NZ King Salmon.
Research firm was founded in 2015 by ex-Goldman Sachs analyst.
